STAT+: Pharmalittle: Global demand for monkeypox vaccine will be hard to meet; Amgen dispute with IRS heats up
Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because that oh-so familiar routine of online meetings and deadlines has returned. But this was predictable, yes? After all, the world — such as it is — keeps spinning, no matter how hard we try to slow it down. So perhaps giving it a nudge in a better direction with a cup or three of stimulation is in order. Our choice today is bourbon pecan. Please feel free to join us. Meanwhile, here is the latest list of interesting items for you to peruse as you start your own journey. We hope your day is productive and meaningful. And of course, do keep in touch. …
Amgen is in a heated fight with the U.S. Internal Revenue Service over its international tax strategy and $10.7 billion in back taxes and penalties that the agency says it is owed, The Wall Street Journal writes. The IRS says that Amgen underreported its taxable income by nearly $24 billion from 2010 to 2015 by inappropriately attributing what the agency says should have been U.S. profits to a Puerto Rico subsidiary that oversees manufacturing of the company’s drugs. The dispute with the IRS is the latest example of heightened government scrutiny of the international tax practices of pharmaceutical, technology, and other companies.
Continue to STAT+ to read the full story…
